Trials / Completed
CompletedNCT03055611
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- Swedish Orphan Biovitrum · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation factor products. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia A and B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELOCTA | Extended half-life factor VIII product |
| DRUG | ALPROLIX | Extended half-life factor IX product |
Timeline
- Start date
- 2017-05-09
- Primary completion
- 2022-04-19
- Completion
- 2022-04-19
- First posted
- 2017-02-16
- Last updated
- 2024-10-02
Locations
22 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03055611. Inclusion in this directory is not an endorsement.